One of the first blockbuster games of the year is almost here - and it's a creepy one. Resident Evil Requiem launches on February 27th, and it's the first all-new RE game since Village in 2021 . It's also a fascinating experience, one that combines the guns-blazing action of Resident Evil 4 with the first-person terror that originated with Resident Evil 7 . In a lot of ways, it's the best of both ...
One of the first blockbuster games of the year is almost here - and it's a creepy one. Resident Evil Requiem launches on February 27th, and it's the first all-new RE game since Village in 2021 . It's also a fascinating experience, one that combines the guns-blazing action of Resident Evil 4 with the first-person terror that originated with Resident Evil 7 . In a lot of ways, it's the best of both worlds, as our review explains . And we're here to talk about it. My colleague Jay Peters and I have been playing the game ahead of launch and will be answering questions from Verge subscribers right here. So if you're curious about how the dual char … Read the full story at The Verge.
The S&P 500 Index ($SPX ) (SPY ) today is up +0.64%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.15%. March E-mini S&P futures (ESH26 ) are up +0.60%, and March E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.64%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.15%. March E-mini S&P futures (ESH26 ) are up +0.60%, and March E-mini Nasdaq futures...
Alexey_Fedoren Wall Street advanced on Wednesday as investors get in position ahead of Nvidia’s ( NVDA ) highly anticipated fourth-quarter earnings report, set for release after the closing bell. Leading the way higher was the tech focused Nasdaq Composite ( COMP:IND ) as it was +1.1%. The benchmark S&P 500 ( SP500 ) was +0.4%, and the blue-chip Dow ( DJI ) was +0.2%. From a sector vantage point, ...
Alexey_Fedoren Wall Street advanced on Wednesday as investors get in position ahead of Nvidia’s ( NVDA ) highly anticipated fourth-quarter earnings report, set for release after the closing bell. Leading the way higher was the tech focused Nasdaq Composite ( COMP:IND ) as it was +1.1%. The benchmark S&P 500 ( SP500 ) was +0.4%, and the blue-chip Dow ( DJI ) was +0.2%. From a sector vantage point, five of the S&P 500’s 11 segments were in positive trading territory, with info tech leading the way. At the other end of the spectrum, energy has suffered the most so far. U.S. Treasury yields moved slightly higher across the curve. The 2-year Treasury yield ( US2Y ) rose to 3.48%, while the 10-year Treasury yield ( US10Y ) reached 4.05%. The 30-year Treasury yield ( US30Y ) stood at 4.70%. As for stocks that were on the move, shares of Albemarle ( ALB ) climbed 8.5%, and shares of First Solar ( FSLR ) came down by 13.4%. More on markets ETFs heavily tied to Nvidia prepare for potential volatility as earnings loom AI, tariffs, Taiwan, and beyond: What prediction markets expect from Nvidia’s earnings call Apollo warns that market structure is growing increasingly fragile S&P 500: Supreme Court Ruling On Tariffs Increases Market Volatility SPY: Tariff Troubles (And Other Developments) Dampen Some Optimism
Aamulya/iStock via Getty Images Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearly psoriasis candidate is undergoing Phase 2a investigation in an ~80-patient study that management expects to yield best-in-class data for a ...
Aamulya/iStock via Getty Images Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearly psoriasis candidate is undergoing Phase 2a investigation in an ~80-patient study that management expects to yield best-in-class data for a ~$30 billion indication in 2H26. With its IL-17 A/F inhibitor ORKA-002 expected to demonstrate three times the half-life of current best-in-class Bimzelx in a healthy subject trial, the upside potential of Oruka merited a deeper dive ahead of its earnings on March 6th. An analysis follows below. ORKA Stock Chart (Seeking Alpha) Company Overview: Oruka Therapeutics, Inc. is a Menlo Park, California-based clinical-stage biopharmaceutical concern focused on the development of therapies for the treatment of chronic skin diseases and other inflammatory and immunology conditions. It is currently advancing two programs through the clinic, including ORKA-001 for the treatment of psoriasis [PSO] and ORKA-002 for the treatment of PsO and other autoimmune indications. Oruka was formed as part of " incubator" Paragon Therapeutics – founded in 2021 – which spun it out and reverse-merged it into failed cardiovascular concern ARCA biopharma in August 2024, while executing a concurrent PIPE financing that raised net proceeds of $188.7 million at $23 per share. The stock trades just under $35.00 a share, translating to an approximate market cap of $1.6 billion. Approach The company’s approach involves engineering monoclonal antibodies to optimize binding affinity and potency while extending their half-lives to reduce the amount of dosing. Greater half-lives are achieved through amino acid modification of the fragment crystallizable [FC] region of the antibody – essentially its tail – that allow it to better survive the lower pH environment in the interior of the endosome. From this platform...
Advanced Micro Devices has recently transformed from emerging artificial intelligence supplier to validated infrastructure partner with its recent deal with Meta , and the market is only beginning to price in what that means. For the past two years, AMD was viewed as a technically capable challenger in artificial intelligence, but one that remained largely unproven at hyperscalers. While its MI300...
Advanced Micro Devices has recently transformed from emerging artificial intelligence supplier to validated infrastructure partner with its recent deal with Meta , and the market is only beginning to price in what that means. For the past two years, AMD was viewed as a technically capable challenger in artificial intelligence, but one that remained largely unproven at hyperscalers. While its MI300 accelerators gained early traction, most deployments were limited to pilot programs and mixed environments rather than full platform adoption. This agreement with Meta confirms that its hardware can operate at the highest tier of global AI infrastructure. At the same time, this validation arrives as Wall Street continues to underestimate the next phase of artificial intelligence. Most forecasts still focus primarily on training workloads. However, the dominant long-term driver of AI spending will be inference, the ongoing compute required to run millions of autonomous, agent-based systems continuously. As agentic AI adoption accelerates, inference demand will grow exponentially. That shift is only beginning to be understood by investors, creating a structural opportunity for companies like AMD positioned at the center of large-scale inference infrastructure. Trade timing & outlook After breaking out above $200 in October 2025, AMD has now firmly retested that level as support following its recent pullback. Holding above $200 opens the path toward a retest of the $240–$270 zone, which marks the upper end of its recent trading range. The recent bounce following the Meta announcement reflects a shift from consolidation to renewed upside momentum. Fundamentals AMD's growth profile remains compelling relative to its industry peers: Forward P/E: ~31x vs. Industry ~33x Expected EPS growth: ~49% vs. Industry ~31% Expected revenue growth: ~34% vs. Industry ~13% Net margins: ~12.5% vs. Industry ~16.6% While margins remain below some peers, AMD's superior growth trajectory reflects i...
(RTTNews) - Stock of Lowe's Companies, Inc. (LOW) is moving down nearly 4 percent on Wednesday morning trading following the announcement of its fourth-quarter results, which saw a decline in earnings to $999 million, or $1.78 per share, compared with $1.125 billion, or $1.99 per
(RTTNews) - Stock of Lowe's Companies, Inc. (LOW) is moving down nearly 4 percent on Wednesday morning trading following the announcement of its fourth-quarter results, which saw a decline in earnings to $999 million, or $1.78 per share, compared with $1.125 billion, or $1.99 per
Wheat is kicking off Wednesday trade with losses of 2 to 4 cents. The wheat complex was weaker on Tuesday. Chicago SRW futures were steady to 2 cents lower. Open interest rose 3,208 contracts on Tuesday. KC HRW futures are down 5 to 6 cents in the front months on...
Wheat is kicking off Wednesday trade with losses of 2 to 4 cents. The wheat complex was weaker on Tuesday. Chicago SRW futures were steady to 2 cents lower. Open interest rose 3,208 contracts on Tuesday. KC HRW futures are down 5 to 6 cents in the front months on...
Live cattle futures posted mixed action on Tuesday, with contracts up a dime to 15 cents lower. Open interest was up 2,371 contracts on Tuesday, with the front two contracts dropping and OI rising in June through December. Cash trade has been quiet so far this week, with last week...
Live cattle futures posted mixed action on Tuesday, with contracts up a dime to 15 cents lower. Open interest was up 2,371 contracts on Tuesday, with the front two contracts dropping and OI rising in June through December. Cash trade has been quiet so far this week, with last week...
Lean hog futures saw gains of $1.70 to $2.10 on Tuesday. Open interest suggests longs coming back in, rising 3,563 contracts. April was the only to see a drop in OI, down 2,006 contracts. USDA’s national base hog price was not reported on Tuesday afternoon, with the 5-day rolling average...
Lean hog futures saw gains of $1.70 to $2.10 on Tuesday. Open interest suggests longs coming back in, rising 3,563 contracts. April was the only to see a drop in OI, down 2,006 contracts. USDA’s national base hog price was not reported on Tuesday afternoon, with the 5-day rolling average...
Orbia Advance Corporation, S.A.B. de C.V. press release ( MXCHF ): Q4 Revenue of $1.88B (+5.6% Y/Y) beats by $20M . Adjusted EBITDA of $236M (-14% Y/Y). 2026 Outlook For 2026, the Company expects full-year EBITDA will be in the range of $1,100M–$1,200M, with capital expenditures expected to be approximately $400M. More on Orbia Advance Corporation, S.A.B. de C.V. Seeking Alpha’s Quant Rating on Or...
Orbia Advance Corporation, S.A.B. de C.V. press release ( MXCHF ): Q4 Revenue of $1.88B (+5.6% Y/Y) beats by $20M . Adjusted EBITDA of $236M (-14% Y/Y). 2026 Outlook For 2026, the Company expects full-year EBITDA will be in the range of $1,100M–$1,200M, with capital expenditures expected to be approximately $400M. More on Orbia Advance Corporation, S.A.B. de C.V. Seeking Alpha’s Quant Rating on Orbia Advance Corporation, S.A.B. de C.V. Historical earnings data for Orbia Advance Corporation, S.A.B. de C.V. Financial information for Orbia Advance Corporation, S.A.B. de C.V.
The sex offender could exploit these masters of the universe because, despite their privilege, they still felt short-changed by life One of the things that has been frequently puzzled over as the effluent of the Epstein story flows on, is how a college dropout who thought it was cool to do typos managed to persuade the world’s most powerful into his lair. What, precisely, was the nature of his “...
The sex offender could exploit these masters of the universe because, despite their privilege, they still felt short-changed by life One of the things that has been frequently puzzled over as the effluent of the Epstein story flows on, is how a college dropout who thought it was cool to do typos managed to persuade the world’s most powerful into his lair. What, precisely, was the nature of his “genius”? Was it blackmail? Was it the social pyramid scheme of using one big name to reel in another? Nothing has come close to explaining it until, with the latest crop of details from the Epstein files, something has become suddenly clear: that it wasn’t the trafficked girls and women who Jeffrey Epstein groomed. The man’s real talent, if we want to call it that, was in the grooming of his cohort of associates. This isn’t to say, of course, that the men and occasional woman who threw in their lot with a man we must straight-facedly refer to as “the dead paedophile” weren’t culpable. Nonetheless, if you study the huge amount of Epstein-related material, from the New York Times’s deep dive into his finances to the vast cache of correspondence contained in the files, a picture emerges of a man who did the kind of number on his peers that you would more commonly see directed at victims. While multiple survivor testimonies indicate that Epstein regarded the girls and women he trafficked as of such low consequence he didn’t even need to bother to groom them – per Virginia Giuffre’s account, Epstein raped her the first time they met – all of his resources, via a variety of tactics, went into capturing the allegiances of powerful men. Emma Brockes is a Guardian columnist Continue reading...
Goalhanger’s Tony Pastor says Serie A has ‘disappeared’ ‘You have to embrace this idea of fragmentation’ Football “has eaten almost every sport worldwide” thanks to its dominance of TV and digital markets, according to the head of the leading podcast production company Goalhanger. Tony Pastor, CEO of the studio behind the Rest is Football among other podcasts, said that broadcasters were strugglin...
Goalhanger’s Tony Pastor says Serie A has ‘disappeared’ ‘You have to embrace this idea of fragmentation’ Football “has eaten almost every sport worldwide” thanks to its dominance of TV and digital markets, according to the head of the leading podcast production company Goalhanger. Tony Pastor, CEO of the studio behind the Rest is Football among other podcasts, said that broadcasters were struggling to get value for money for sports rights and that competitions should “embrace fragmentation” to reach audiences where they are. Continue reading...